{
    "clinical_study": {
        "@rank": "131186", 
        "arm_group": {
            "arm_group_label": "Primary Arm", 
            "arm_group_type": "Experimental", 
            "description": "There will be a scan of the brain to determine where to focus the radiation treatment, the 18F-DOPA PET/CT, standard and advanced MRI Imaging will occur about 2 weeks prior to radiation therapy. After radiation therapy (3 - 6 weeks post therapy) another 18F-DOPA PET/CT standard and advanced MRI Imaging will occur. Then the 18F-DOPA PET/CT standard and advanced MRI Imaging will occur as clinically indicated until progression or 5 years have passed since radiation therapy occurred."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to use a nutrient called 18F-FDOPA and PET/CT scan to help\n      determine where and how big the tumor is, as well as how aggressive the tumor is. This will\n      help treating physicians to target diseased areas with higher than standard doses of\n      radiation, in order to improve the effectiveness of radiation in this tumor."
        }, 
        "brief_title": "Evaluating the Impact of 18F-DOPA-PET on Radiotherapy Planning for Newly Diagnosed Gliomas", 
        "condition": "Newly Diagnosed Gliomas", 
        "condition_browse": {
            "mesh_term": "Glioma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226518 years.\n\n          -  Histologically confirmed newly diagnosed high-grade malignant glioma.\n\n          -  Planned radiation treatments at Mayo Clinic Rochester.\n\n          -  Willing to sign release of information for any radiation and/or follow-up records.\n\n          -  Provide informed written consent.\n\n          -  Patients with eGFR \u2265 60 mg/min/1.72m2\n\n          -  Ability to complete questionnaire(s) by themselves or with assistance.\n\n        Exclusion Criteria:\n\n          -  Patients diagnosed with anaplastic oligodendroglioma\n\n          -  Unable to undergo MRI scans with contrast (e.g. cardiac pacemaker, defibrillator,\n             kidney failure).\n\n          -  Unable to undergo an 18F-DOPA PET scan (e.g. Parkinson's Disease, taking\n             anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from\n             discontinuance of dopamine agonists)\n\n          -  Any of the following:\n\n          -  Pregnant women\n\n          -  Nursing women\n\n          -  Men or women of childbearing potential who are unwilling to employ    adequate\n             contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "115", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991977", 
            "org_study_id": "MC1374", 
            "secondary_id": "13-005106"
        }, 
        "intervention": {
            "arm_group_label": "Primary Arm", 
            "intervention_name": "Standard Radiation Therapy", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 20, 2013", 
        "location": {
            "contact": {
                "email": "laack.nadia@mayo.edu", 
                "last_name": "Nadia N Laack, M.D", 
                "phone": "507-284-2511"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic Rochester"
            }, 
            "investigator": [
                {
                    "last_name": "Nadia N. Laack, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Debra H. Brinkman, Ph.D", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluating the Impact of 18F-DOPA-PET on Radiotherapy Planning for Newly Diagnosed Gliomas", 
        "overall_contact": {
            "email": "Laack.Nadia@mayo.edu", 
            "last_name": "Nadia N. Laack, M.D.", 
            "phone": "507-284-3261"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Compare progression free survival at 12 months for Grade IV glioma patients after radiation therapy targeting volumes designed with both 18F-DOPA PET and conventional MR image information with historical controls from Mayo Clinic Rochester patients treated on NCCTG clinical trials.", 
            "measure": "Compare progression free survival at 12 Months", 
            "safety_issue": "No", 
            "time_frame": "12 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991977"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Nadia N. Laack, M.D.", 
            "investigator_title": "Principle Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}